Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25980403 | 0.91 | TAAR1 (0.53) | SMN1; SMN2KDM4EALDH1A1HTTTAAR1 | |
| SCHEMBL8785364 | 0.91 | TAAR1 (0.53) | SMN1; SMN2KDM4EALDH1A1HTTTAAR1 | |
| SCHEMBL29587500 | 0.87 | TAAR1 (0.60) | TAAR1IDO1AGXT | |
| SCHEMBL96382 | 0.87 | TAAR1 (0.60) | TAAR1IDO1AGXT | |
| SCHEMBL1746839 | 0.86 | FFAR1 (0.53) | SMN1; SMN2KDM4EALDH1A1HTTLTA4H | |
| SCHEMBL29661187 | 0.85 | LTA4H (0.67) | SMN1; SMN2KDM4EALDH1A1HTTLTA4H | |
| SCHEMBL358425 | 0.85 | LTA4H (0.67) | SMN1; SMN2KDM4EALDH1A1HTTLTA4H | |
| SCHEMBL327459 | 0.84 | KDM4E (0.62) | SMN1; SMN2KDM4EALDH1A1HTTLTA4H | |
| SCHEMBL30979265 | 0.84 | LTA4H (0.55) | SMN1; SMN2LTA4H | |
| SCHEMBL5112767 | 0.84 | LTA4H (0.55) | SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2959918-B1 | ANTI-MALIGNANT TUMOR AGENT COMPOSITION | J PHARMA CO LTD (JP) | 2019-05-22 | — | — | EP | disclosed |
| US-10172835-B2 | Anticancer agent composition | J-PHARMA CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20160279103-A1 | AN ANTICANCER AGENT COMPOSITION | J-PHARMA CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-2959918-A1 | ANTI-MALIGNANT TUMOR AGENT COMPOSITION | J-Pharma Co., Ltd. (JP) | 2015-12-30 | — | — | EP | disclosed |
| EP-1481965-B1 | AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS | ENDO HITOSHI (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-7345068-B2 | Aromatic amino acid derivatives and medicinal compositions | Endou, Hitoshi (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119256-A1 | Aromatic amino acid derivates and medicinal compositions | HITOSHI ENDOU (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1481965-A1 | AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS | Endo, Hitoshi (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | SMN1; SMN2 4795/4885KDM4E 2595/4885ALDH1A1 3163/4885 |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | SMN1; SMN2 4831/4885KDM4E 3112/4885ALDH1A1 1677/4885 |
| US-20160279103-A1 | AN ANTICANCER AGENT COMPOSITION | TUBB1, TUBA1A, TUBA1C | SMN1; SMN2 1404/4885KDM4E 4145/4885ALDH1A1 2612/4885 |
| US-20050119256-A1 | Aromatic amino acid derivates and medicinal compositions | SLC7A1, SLC1A5, SLC7A5 | SMN1; SMN2 4118/4885KDM4E 1714/4885ALDH1A1 869/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | SMN1; SMN2 4814/4885KDM4E 3245/4885ALDH1A1 1459/4885 |
| US-10172835-B2 | Anticancer agent composition | TOP1, TUBB1, TUBA1A | SMN1; SMN2 1763/4885KDM4E 4258/4885ALDH1A1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.